Literature DB >> 17879147

Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg Effect", i.e., elevated glycolysis in the presence of oxygen.

Peter L Pedersen1.   

Abstract

As a new faculty member at The Johns Hopkins University, School of Medicine, the author began research on cancer in 1969 because this frequently fatal disease touched many whom he knew. He was intrigued with its viscous nature, the failure of all who studied it to find a cure, and also fascinated by the pioneering work of Otto Warburg, a biochemical legend and Nobel laureate. Warburg who died 1 year later in 1970 had shown in the 1920s that the most striking biochemical phenotype of cancers is their aberrant energy metabolism. Unlike normal tissues that derive most of their energy (ATP) by metabolizing the sugar glucose to carbon dioxide and water, a process that involves oxygen-dependent organelles called "mitochondria", Warburg showed that cancers frequently rely less on mitochondria and obtain as much as 50% of their ATP by metabolizing glucose directly to lactic acid, even in the presence of oxygen. This frequent phenotype of cancers became known as the "Warburg effect", and the author of this review strongly believed its understanding would facilitate the discovery of a cure. Following in the final footsteps of Warburg and caught in the midst of an unpleasant anti-Warburg, anti-metabolic era, the author and his students/collaborators began quietly to identify the key molecular events involved in the "Warburg effect". Here, the author describes via a series of sequential discoveries touching five decades how despite some impairment in the respiratory capacity of malignant tumors, that hexokinase 2 (HK-2), its mitochondrial receptor (VDAC), and the gene that encodes HK-2 (HK-2 gene) play the most pivotal and direct roles in the "Warburg effect". They discovered also that like a "Trojan horse" the simple lactic acid analog 3-bromopyruvate selectively enters the cells of cancerous animal tumors that exhibit the "Warburg effect" and quickly dissipates their energy (ATP) production factories (i.e., glycolysis and mitochondria) resulting in tumor destruction without harm to the animals.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17879147     DOI: 10.1007/s10863-007-9094-x

Source DB:  PubMed          Journal:  J Bioenerg Biomembr        ISSN: 0145-479X            Impact factor:   2.945


  68 in total

1.  On respiratory impairment in cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-08-10       Impact factor: 47.728

2.  On the role of VDAC in apoptosis: fact and fiction.

Authors:  Tatiana K Rostovtseva; Wenzhi Tan; Marco Colombini
Journal:  J Bioenerg Biomembr       Date:  2005-06       Impact factor: 2.945

Review 3.  Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development.

Authors:  Gary J Kelloff; John M Hoffman; Bruce Johnson; Howard I Scher; Barry A Siegel; Edward Y Cheng; Bruce D Cheson; Joyce O'shaughnessy; Kathryn Z Guyton; David A Mankoff; Lalitha Shankar; Steven M Larson; Caroline C Sigman; Richard L Schilsky; Daniel C Sullivan
Journal:  Clin Cancer Res       Date:  2005-04-15       Impact factor: 12.531

4.  Altered metabolic states do not change the intracellular distribution of hexokinase in Zajdela hepatoma ascites cells.

Authors:  B D Nelson; F Kabir; P Muchiri
Journal:  Biochem J       Date:  1984-04-01       Impact factor: 3.857

5.  Hexokinase receptor complex in hepatoma mitochondria: evidence from N,N'-dicyclohexylcarbodiimide-labeling studies for the involvement of the pore-forming protein VDAC.

Authors:  R A Nakashima; P S Mangan; M Colombini; P L Pedersen
Journal:  Biochemistry       Date:  1986-03-11       Impact factor: 3.162

6.  Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes.

Authors:  B Altenberg; K O Greulich
Journal:  Genomics       Date:  2004-12       Impact factor: 5.736

7.  Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention.

Authors:  Peter L Pedersen; Saroj Mathupala; Annette Rempel; J F Geschwind; Young Hee Ko
Journal:  Biochim Biophys Acta       Date:  2002-09-10

8.  Energy metabolism of tumor cells. Requirement for a form of hexokinase with a propensity for mitochondrial binding.

Authors:  E Bustamante; H P Morris; P L Pedersen
Journal:  J Biol Chem       Date:  1981-08-25       Impact factor: 5.157

9.  Intracellular localization and properties of particulate hexokinase in the Novikoff ascites tumor. Evidence for an outer mitochondrial membrane location.

Authors:  D M Parry; P L Pedersen
Journal:  J Biol Chem       Date:  1983-09-25       Impact factor: 5.157

10.  Pyruvate transport in tumour-cell mitochondria.

Authors:  M L Eboli; G Paradies; T Galeotti; S Papa
Journal:  Biochim Biophys Acta       Date:  1977-04-11
View more
  181 in total

Review 1.  Genetic insights into OXPHOS defect and its role in cancer.

Authors:  Dhyan Chandra; Keshav K Singh
Journal:  Biochim Biophys Acta       Date:  2010-11-11

2.  Mitochondrial dysfunction and effect of antiglycolytic bromopyruvic acid in GL15 glioblastoma cells.

Authors:  Lara Macchioni; Magdalena Davidescu; Miriam Sciaccaluga; Cristina Marchetti; Graziella Migliorati; Stefano Coaccioli; Rita Roberti; Lanfranco Corazzi; Emilia Castigli
Journal:  J Bioenerg Biomembr       Date:  2011-07-21       Impact factor: 2.945

Review 3.  The diverse role of the PPARγ coactivator 1 family of transcriptional coactivators in cancer.

Authors:  Geoffrey D Girnun
Journal:  Semin Cell Dev Biol       Date:  2012-01-21       Impact factor: 7.727

4.  MicroRNA-143 (miR-143) regulates cancer glycolysis via targeting hexokinase 2 gene.

Authors:  Rong Fang; Tian Xiao; Zhaoyuan Fang; Yihua Sun; Fei Li; Yijun Gao; Yan Feng; Li Li; Ye Wang; Xiaolong Liu; Haiquan Chen; Xin-Yuan Liu; Hongbin Ji
Journal:  J Biol Chem       Date:  2012-05-16       Impact factor: 5.157

5.  Bromopyruvate mediates autophagy and cardiolipin degradation to monolyso-cardiolipin in GL15 glioblastoma cells.

Authors:  Magdalena Davidescu; Miriam Sciaccaluga; Lara Macchioni; Roberto Angelini; Patrizia Lopalco; Maria Grazia Rambotti; Rita Roberti; Angela Corcelli; Emilia Castigli; Lanfranco Corazzi
Journal:  J Bioenerg Biomembr       Date:  2012-02-09       Impact factor: 2.945

6.  Flow cytometric evaluation of the effects of 3-bromopyruvate (3BP) and dichloracetate (DCA) on THP-1 cells: a multiparameter analysis.

Authors:  Harrie A Verhoeven; Leo J L D van Griensven
Journal:  J Bioenerg Biomembr       Date:  2012-02-09       Impact factor: 2.945

7.  Glucose sensing by MondoA:Mlx complexes: a role for hexokinases and direct regulation of thioredoxin-interacting protein expression.

Authors:  Carrie A Stoltzman; Christopher W Peterson; Kevin T Breen; Deborah M Muoio; Andrew N Billin; Donald E Ayer
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-05       Impact factor: 11.205

8.  A novel role for mitochondria in regulating epigenetic modification in the nucleus.

Authors:  Dominic J Smiraglia; Mariola Kulawiec; Gaia L Bistulfi; Sampa Ghoshal Gupta; Keshav K Singh
Journal:  Cancer Biol Ther       Date:  2008-08-01       Impact factor: 4.742

9.  Hexokinase II detachment from the mitochondria potentiates cisplatin induced cytotoxicity through a caspase-2 dependent mechanism.

Authors:  Nataly Shulga; Robin Wilson-Smith; John G Pastorino
Journal:  Cell Cycle       Date:  2009-10-19       Impact factor: 4.534

10.  Mitochondrial bioenergetic adaptations of breast cancer cells to aglycemia and hypoxia.

Authors:  Katarína Smolková; Nadège Bellance; Francesca Scandurra; Elisabeth Génot; Erich Gnaiger; Lydie Plecitá-Hlavatá; Petr Jezek; Rodrigue Rossignol
Journal:  J Bioenerg Biomembr       Date:  2010-01-19       Impact factor: 2.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.